Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 228.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.59M |
| Shares Out | 29.77M |
| EPS (ttm) | -2.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $7.67 |
| Previous Close | $7.25 |
| Change ($) | 0.42 |
| Change (%) | 5.79% |
| Day's Open | 7.18 |
| Day's Range | 7.12 - 7.73 |
| Day's Volume | 107,610 |
| 52-Week Range | 1.70 - 22.50 |
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innov...
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innov...
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commer...
MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commer...
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of inno...
Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.
When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.
MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Milestone Pharmaceuticals (MIST) news for Thursday includes new guidelines for a clinical study pushing MIST stock higher.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update.
MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.
As of late, it has definitely been a great time to be an investor in Milestone Pharmaceuticals.
Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals
Top Ranked Momentum Stocks to Buy for May 19th
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova...
Milestone Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Shares of small-cap Milestone Pharmaceuticals Inc (NASDAQ: MIST) were losing three-quarters of their value Tuesday on the back of a negative clinical readout.
Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.
About MIST
Milestone Pharmaceuticals, a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
| Industry Biotechnology | Founded 2003 |
| CEO Joseph G. Oliveto | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol MIST |
Analyst Forecasts
According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 72.75% from the latest price.